Dentate Update: Imaging Features of Entities That Affect the Dentate Nucleus

REFERENCES

1. 1.↵
   2. Rhoton AL Jr.

   . Cerebellum and fourth ventricle. Neurosurgery 2000;47:S7–27 doi:10.1097/00006123-200009001-00007 pmid:10983303

   CrossRefPubMed
2. 2.↵
   2. Akakin A,
   3. Peris-Celda M,
   4. Kilic T, et al

   . The dentate nucleus and its projection system in the human cerebellum: the dentate nucleus microsurgical anatomical study. Neurosurgery 2014;74:401–24; discussion 424–25 doi:10.1227/NEU.0000000000000293 pmid:24448179

   CrossRefPubMed
3. 3.↵
   2. O'Halloran CJ,
   3. Kinsella GJ,
   4. Storey E

   . The cerebellum and neuropsychological functioning: a critical review. J Clin Exp Neuropsychol 2012;34:35–56 doi:10.1080/13803395.2011.614599 pmid:22047489

   CrossRefPubMed
4. 4.↵
   2. Schmahmann JD,
   3. Sherman JC

   . The cerebellar cognitive affective syndrome. Brain 1998;121(pt 4):561–79 doi:10.1093/brain/121.4.561 pmid:9577385

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Timmann D,
   3. Drepper J,
   4. Frings M, et al

   . The human cerebellum contributes to motor, emotional and cognitive associative learning: a review. Cortex 2010;46:845–57 doi:10.1016/j.cortex.2009.06.009 pmid:19665115

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Salamon N,
   3. Sicotte N,
   4. Drain A, et al

   . White matter fiber tractography and color mapping of the normal human cerebellum with diffusion tensor imaging. J Neuroradiol 2007;34:115–28 doi:10.1016/j.neurad.2007.03.002 pmid:17481730

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Suzuki L,
   3. Coulon P,
   4. Sabel-Goedknegt EH, et al

   . Organization of cerebral projections to identified cerebellar zones in the posterior cerebellum of the rat. J Neurosci 2012;32:10854–69 doi:10.1523/JNEUROSCI.0857-12.2012 pmid:22875920

   Abstract/FREE Full Text
8. 8.↵
   2. Hoover JE,
   3. Strick PL

   . The organization of cerebellar and basal ganglia outputs to primary motor cortex as revealed by retrograde transneuronal transport of herpes simplex virus type I. J Neurosci 1999;19:1446–63 pmid:9952421

   Abstract/FREE Full Text
9. 9.↵
   2. Guillan G,
   3. Mollaret P

   . Two cases of synchronous and rhythmical velopharyngo-laryngo-oculo-diaphragmatic myoclonus: the anatomical and physiopathological problem of this syndrome. Rev Neurol 1931;2:545–66
10. 10.↵
    2. Murdoch S,
    3. Shah P,
    4. Jampana R

    . The Guillain-Mollaret triangle in action. Pract Neurol 2016;16:243–46 doi:10.1136/practneurol-2015-001142 pmid:26740379

    Abstract/FREE Full Text
11. 11.↵
    2. Shaikh AG,
    3. Hong S,
    4. Liao K, et al

    . Oculopalatal tremor explained by a model of inferior olivary hypertrophy and cerebellar plasticity. Brain 2010;133:923–40 doi:10.1093/brain/awp323 pmid:20080879

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Wakai S,
    3. Nagai M

    . Histological verification of microaneurysms as a cause of cerebral-hemorrhage in surgical specimens. J Neurol Neurosugr Psychiatry 1989;52:595–99 doi:10.1136/jnnp.52.5.595 pmid:2732728

    Abstract/FREE Full Text
13. 13.↵
    2. Kanno T,
    3. Sano H,
    4. Shinomiya Y, et al

    . Role of surgery in hypertensive intracerebral hematoma: a comparative study of 305 nonsurgical and 154 surgical cases. J Neurosurg 1984;61:1091–99 doi:10.3171/jns.1984.61.6.1091 pmid:6502238

    CrossRefPubMed
14. 14.↵
    2. Fazekas F,
    3. Kleinert R,
    4. Roob G, et al

    . Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999;20:637–42 pmid:10319975

    Abstract/FREE Full Text
15. 15.↵
    2. Frytak S,
    3. Moertel CH,
    4. Childs DS

    . Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 1978;88:361–62 doi:10.7326/0003-4819-88-3-361 pmid:629500

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Ahmed A,
    3. Loes DJ,
    4. Bressler EL

    . Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy. Neurology 1995;45:588–89 doi:10.1212/WNL.45.3.588 pmid:7898724

    CrossRefPubMed
17. 17.↵
    2. Horlen CK,
    3. Seifert CF,
    4. Malouf CS

    . Toxic metronidazole-induced MRI changes. Ann Pharmacother 2000;34:1273–75 doi:10.1345/aph.10028 pmid:11098341

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Woodruff BK,
    3. Wijdicks EF,
    4. Marshall WF

    . Reversible metronidazole-induced lesions of the cerebellar dentate nuclei. N Engl J Med 2002;346:68–69 doi:10.1056/NEJM200201033460117 pmid:11778010

    CrossRefPubMedWeb of Science
19. 19.↵
    2. White GW,
    3. Gibby WA,
    4. Tweedle MF

    . Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272–78 doi:10.1097/01.rli.0000186569.32408.95 pmid:16481910

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Kanda T,
    3. Ishii K,
    4. Kawaguchi H, et al

    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

    CrossRefPubMed
21. 21.↵
    2. Radbruch A,
    3. Weberling LD,
    4. Kieslich PJ, et al

    . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275:783–91 doi:10.1148/radiol.2015150337 pmid:25848905

    CrossRefPubMed
22. 22.↵
    2. Stojanov D,
    3. Aracki-Trenkic A,
    4. Benedeto-Stojanov D

    . Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. Neuroradiology 2016;58:433–41 doi:10.1007/s00234-016-1658-1 pmid:26873830

    CrossRefPubMed
23. 23.↵
    2. McDonald RJ,
    3. McDonald JS,
    4. Kallmes DF, et al

    . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

    CrossRefPubMed
24. 24.↵
    2. Welk B,
    3. McArthur E,
    4. Morrow SA, et al

    . Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 2016;316:96–98 doi:10.1001/jama.2016.8096 pmid:27380348

    CrossRefPubMed
25. 25.↵
    2. Noseworthy JH,
    3. Lucchinetti C,
    4. Rodriguez M, et al

    . Multiple sclerosis. N Engl J Med 2000;343:938–52 doi:10.1056/NEJM200009283431307 pmid:11006371

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Anderson VM,
    3. Fisniku LK,
    4. Altmann DR, et al

    . MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction. Mult Scler 2009;15:811–17 doi:10.1177/1352458508101934 pmid:19465449

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Fisher E,
    3. Lee JC,
    4. Nakamura K, et al

    . Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255–65 doi:10.1002/ana.21436 pmid:18661561

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Gilmore CP,
    3. Geurts JJ,
    4. Evangelou N, et al

    . Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging. Mult Scler 2009;15:180–88 pmid:18845658

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Du SL,
    3. Sah SK,
    4. Zeng C, et al

    . Iron deposition in the gray matter in patients with relapse-remitting multiple sclerosis: a longitudinal study using three-dimensional (3D)-enhanced T2*-weighted angiography (ESWAN). Eur J Radiol 2015;84:1325–32 doi:10.1016/j.ejrad.2015.04.013 pmid:25959392

    CrossRefPubMed
30. 30.↵
    2. Roccatagliata L,
    3. Vuolo L,
    4. Bonzano L, et al

    . Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology 2009;251:503–10 doi:10.1148/radiol.2511081269 pmid:19401576

    CrossRefPubMed
31. 31.↵
    2. Tjoa CW,
    3. Benedict RH,
    4. Weinstock-Guttman B, et al

    . MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci 2005;234:17–24 doi:10.1016/j.jns.2005.02.009 pmid:15993137

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Pawate S,
    3. Wang L,
    4. Song Y, et al

    . Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies. J Neuroimaging 2012;22:137–44 doi:10.1111/j.1552-6569.2011.00622.x pmid:21707826

    CrossRefPubMed
33. 33.↵
    2. Stankiewicz JM,
    3. Neema M,
    4. Ceccarelli A

    . Iron and multiple sclerosis. Neurobiol Aging 2014;35(suppl 2):S51–58 doi:10.1016/j.neurobiolaging.2014.03.039 pmid:24929968

    CrossRefPubMed
34. 34.↵
    2. Hogarth P

    . Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord 2015;8:1–13 doi:10.14802/jmd.14034 pmid:25614780

    CrossRefPubMed
35. 35.↵
    2. Salomão RP,
    3. Pedroso JL,
    4. Gama MT, et al

    . A diagnostic approach for neurodegeneration with brain iron accumulation: clinical features, genetics and brain imaging. Arq Neuropsiquiatr 2016;74:587–96 doi:10.1590/0004-282X20160080 pmid:27487380

    CrossRefPubMed
36. 36.↵
    2. Saleem S,
    3. Aslam HM,
    4. Anwar M, et al

    . Fahr's syndrome: literature review of current evidence. Orphanet J Rare Dis 2013;8:156 doi:10.1186/1750-1172-8-156 pmid:24098952

    CrossRefPubMed
37. 37.↵
    2. Avrahami E,
    3. Cohn DF,
    4. Feibel M, et al

    . MRI demonstration and CT correlation of the brain in patients with idiopathic intracerebral calcification. J Neurol 1994;241:381–84 doi:10.1007/BF02033355 pmid:7931433

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Elshimali Y

    . The value of differential diagnosis of Fahr's disease by radiology. Internet J Radiol 2004;4. http://ispub.com/IJRA/4/1/9320. Accessed April 3, 2017.
39. 39.↵
    2. Govindarajan A

    . Imaging in Fahr's disease: how CT and MRI differ? BMJ Case Rep 2013;2013 doi:10.1136/bcr-2013-201523 pmid:24285810

    FREE Full Text
40. 40.↵
    2. Kobari M,
    3. Nogawa S,
    4. Sugimoto Y, et al

    . Familial idiopathic brain calcification with autosomal dominant inheritance. Neurology 1997;48:645–49 doi:10.1212/WNL.48.3.645 pmid:9065541

    Abstract/FREE Full Text
41. 41.↵
    2. Castro-Gago M,
    3. Blanco-Barca MO,
    4. Campos-González Y, et al

    . Epidemiology of pediatric mitochondrial respiratory chain disorders in northwest Spain. Pediatr Neurol 2006;34:204–11 doi:10.1016/j.pediatrneurol.2005.07.011 pmid:16504790

    CrossRefPubMedWeb of Science
42. 42.↵
    2. Zhu ZQ,
    3. Yao JB,
    4. Johns T, et al

    . SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet 1998;20:337–43 doi:10.1038/3804 pmid:9843204

    CrossRefPubMedWeb of Science
43. 43.↵
    2. Lee HF,
    3. Tsai CR,
    4. Chi CS, et al

    . Leigh syndrome: clinical and neuroimaging follow-up. Pediatr Neurol 2009;40:88–93 doi:10.1016/j.pediatrneurol.2008.09.020 pmid:19135620

    CrossRefPubMedWeb of Science
44. 44.↵
    2. Finsterer J

    . Leigh and Leigh-like syndrome in children and adults. Pediatr Neurol 2008;39:223–35 doi:10.1016/j.pediatrneurol.2008.07.013 pmid:18805359

    CrossRefPubMedWeb of Science
45. 45.↵
    2. Arii J,
    3. Tanabe Y

    . Leigh syndrome: serial MR imaging and clinical follow-up. AJNR Am J Neuroradiol 2000;21:1502–09 pmid:11003287

    Abstract/FREE Full Text
46. 46.↵
    2. Sonam K,
    3. Khan NA,
    4. Bindu PS, et al

    . Clinical and magnetic resonance imaging findings in patients with Leigh syndrome and SURF1 mutations. Brain Dev 2014;36:807–12 doi:10.1016/j.braindev.2013.10.012 pmid:24262866

    CrossRefPubMed
47. 47.↵
    2. Pandolfo M

    . Friedreich ataxia: the clinical picture. J Neurol 2009;256(suppl 1):3–8 doi:10.1007/s00415-009-1002-3 pmid:19283344

    CrossRefPubMedWeb of Science
48. 48.↵
    2. Koeppen AH

    . Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 2011;303:1–12 doi:10.1016/j.jns.2011.01.010 pmid:21315377

    CrossRefPubMed
49. 49.↵
    2. Mascalchi M,
    3. Salvi F,
    4. Piacentini S, et al

    . Friedreich's ataxia: MR findings involving the cervical portion of the spinal cord. AJR Am J Roentgenol 1994;163:187–91 doi:10.2214/ajr.163.1.8010211 pmid:8010211

    CrossRefPubMedWeb of Science
50. 50.↵
    2. Koeppen AH,
    3. Michael SC,
    4. Knutson MD, et al

    . The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol 2007;114:163–73 doi:10.1007/s00401-007-0220-y pmid:17443334

    CrossRefPubMedWeb of Science
51. 51.↵
    2. Koeppen AH,
    3. Ramirez RL,
    4. Yu D, et al

    . Friedreich's ataxia causes redistribution of iron, copper, and zinc in the dentate nucleus. Cerebellum 2012;11:845–60 doi:10.1007/s12311-012-0383-5 pmid:22562713

    CrossRefPubMed
52. 52.↵
    2. Selvadurai LP,
    3. Harding IH,
    4. Corben LA, et al

    . Cerebral and cerebellar grey matter atrophy in Friedreich ataxia: the IMAGE-FRDA study. J Neurol 2016;263:2215–23 doi:10.1007/s00415-016-8252-7 pmid:27522354

    CrossRefPubMed
53. 53.↵
    2. Rizzo G,
    3. Tonon C,
    4. Valentino ML, et al

    . Brain diffusion-weighted imaging in Friedreich's ataxia. Mov Disord 2011;26:705–12 doi:10.1002/mds.23518 pmid:21370259

    CrossRefPubMed
54. 54.↵
    2. Feigenbaum A,
    3. Moore R,
    4. Clarke J, et al

    . Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay. Am J Med Genet A 2004;124A:142–47 doi:10.1002/ajmg.a.20334 pmid:14699612

    CrossRefPubMed
55. 55.↵
    2. Kronn D,
    3. Oddoux C,
    4. Phillips J, et al

    . Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet 1995;57:1250–52 pmid:7485179

    PubMedWeb of Science
56. 56.↵
    2. Matalon R,
    3. Michals K,
    4. Sebesta D, et al

    . Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988;29:463–71 doi:10.1002/ajmg.1320290234 pmid:3354621

    CrossRefPubMedWeb of Science
57. 57.↵
    2. Namboodiri AM,
    3. Peethambaran A,
    4. Mathew R, et al

    . Canavan disease and the role of N-acetylaspartate in myelin synthesis. Mol Cell Endocrinol 2006;252:216–23 doi:10.1016/j.mce.2006.03.016 pmid:16647192

    CrossRefPubMedWeb of Science
58. 58.↵
    2. Brismar J,
    3. Brismar G,
    4. Gascon G, et al

    . Canavan disease: CT and MR imaging of the brain. AJNR Am J Neuroradiol 1990;11:805–10 pmid:2114773

    Abstract/FREE Full Text
59. 59.↵
    2. Sener RN

    . Canavan disease: diffusion magnetic resonance imaging findings. J Comput Assist Tomogr 2003;27:30–33 doi:10.1097/00004728-200301000-00006 pmid:12544239

    CrossRefPubMed
60. 60.↵
    2. McAdams HP,
    3. Geyer CA,
    4. Done SL, et al

    . CT and MR imaging of Canavan disease. AJNR Am J Neuroradiol 1990;11:397–99 pmid:2107726

    FREE Full Text
61. 61.↵
    2. Wittsack HJ,
    3. Kugel H,
    4. Roth B, et al

    . Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease. J Magn Reson Imaging 1996;6:889–93 doi:10.1002/jmri.1880060609 pmid:8956134

    CrossRefPubMedWeb of Science
62. 62.↵
    2. Lindner M,
    3. Kölker S,
    4. Schulze A, et al

    . Neonatal screening for glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004;27:851–59 doi:10.1023/B:BOLI.0000045769.96657.af pmid:15505392

    CrossRefPubMedWeb of Science
63. 63.↵
    2. Mohammad SA,
    3. Abdelkhalek HS,
    4. Ahmed KA, et al

    . Glutaric aciduria type 1: neuroimaging features with clinical correlation. Pediatr Radiol 2015;45:1696–705 doi:10.1007/s00247-015-3395-8 pmid:26111870

    CrossRefPubMed
64. 64.↵
    2. Wang Q,
    3. Li X,
    4. Ding Y, et al

    . Clinical and mutational spectra of 23 Chinese patients with glutaric aciduria type 1. Brain Dev 2014;36:813–22 doi:10.1016/j.braindev.2013.11.006 pmid:24332224

    CrossRefPubMed
65. 65.↵
    2. Brismar J,
    3. Ozand PT

    . CT and MR of the brain in glutaric acidemia type I: a review of 59 published cases and a report of 5 new patients. AJNR Am J Neuroradiol 1995;16:675–83 pmid:7611022

    Abstract
66. 66.↵
    2. Vester ME,
    3. Visser G,
    4. Wijburg FA, et al

    . Occurrence of subdural hematomas in Dutch glutaric aciduria type 1 patients. Eur J Pediatr 2016;175:1001–06 doi:10.1007/s00431-016-2734-6 pmid:27246831

    CrossRefPubMed
67. 67.↵
    2. Harper PA,
    3. Healy PJ,
    4. Dennis JA

    . Maple Syrup Urine Disease (Branched-Chain Ketoaciduria). New York: McGraw-Hill; 2001:1971–2006
68. 68.↵
    2. Brismar J,
    3. Aqeel A,
    4. Brismar G, et al

    . Maple syrup urine disease: findings on CT and MR scans of the brain in 10 infants. AJNR Am J Neuroradiol 1990;11:1219–28 pmid:2124065

    Abstract/FREE Full Text
69. 69.↵
    2. Gupta AK,
    3. Chowdhury V,
    4. Khandelwal N

    . Diagnostic Radiology Paediatric Imaging. New Delhi: Jaypee Brothers Medical Publishers; 2011:522